Enhancement by cyclosporin A of taxol-induced apoptosis of human urinary bladder cancer cells

[1]  Cheryl Brantley-Finley,et al.  Vinblastine-induced Phosphorylation of Bcl-2 and Bcl-XL Is Mediated by JNK and Occurs in Parallel with Inactivation of the Raf-1/MEK/ERK Cascade* , 2000, The Journal of Biological Chemistry.

[2]  D. Lamm,et al.  Intravesical therapy for bladder cancer. , 2000, Urology.

[3]  Kazuhito Yamamoto,et al.  BCL-2 Is Phosphorylated and Inactivated by an ASK1/Jun N-Terminal Protein Kinase Pathway Normally Activated at G2/M , 1999, Molecular and Cellular Biology.

[4]  T. Fojo,et al.  Molecular effects of paclitaxel: Myths and reality (a critical review) , 1999, International journal of cancer.

[5]  J C Reed,et al.  Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. , 1999, Science.

[6]  R. K Srivastava,et al.  Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Z. Oltvai,et al.  Interleukin-3 Induces the Phosphorylation of a Distinct Fraction of Bcl-2* , 1999, The Journal of Biological Chemistry.

[8]  S. Haldar,et al.  Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. , 1998, International journal of oncology.

[9]  C. Martínez-A,et al.  The Bcl-2 gene is differentially regulated by IL-2 and IL-4: role of the transcription factor NF-AT , 1998, Oncogene.

[10]  K. Bhalla,et al.  "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. , 1998, Cancer research.

[11]  S. Korsmeyer,et al.  Involvement of Microtubules in the Regulation of Bcl2 Phosphorylation and Apoptosis through Cyclic AMP-Dependent Protein Kinase , 1998, Molecular and Cellular Biology.

[12]  Hao Ren,et al.  Regulation of the Calmodulin-stimulated Protein Phosphatase, Calcineurin* , 1998, The Journal of Biological Chemistry.

[13]  P. Stemmer,et al.  Cyclosporin A has low potency as a calcineurin inhibitor in cells expressing high levels of P-glycoprotein. , 1998, Life sciences.

[14]  C. Croce,et al.  Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. , 1998, Cancer research.

[15]  T. Fojo,et al.  Microtubule-interfering Agents Activate c-Jun N-terminal Kinase/Stress-activated Protein Kinase through Both Ras and Apoptosis Signal-regulating Kinase Pathways* , 1998, The Journal of Biological Chemistry.

[16]  M. Muda,et al.  Bcl-2 Undergoes Phosphorylation by c-Jun N-terminal Kinase/Stress-activated Protein Kinases in the Presence of the Constitutively Active GTP-binding Protein Rac1* , 1997, The Journal of Biological Chemistry.

[17]  W. Fair,et al.  The treated natural history of high risk superficial bladder cancer: 15-year outcome. , 1997, The Journal of urology.

[18]  F. Shibasaki,et al.  Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2 , 1997, Nature.

[19]  S. Fesik,et al.  Identification of a novel regulatory domain in Bcl‐xL and Bcl‐2 , 1997, The EMBO journal.

[20]  O. Nativ,et al.  Anti‐neoplastic activity of paclitaxel on experimental superficial bladder cancer: In vivo and in vitro studies , 1997, International journal of cancer.

[21]  C. Croce,et al.  Bcl2 is the guardian of microtubule integrity. , 1997, Cancer research.

[22]  S. Korsmeyer,et al.  Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.

[23]  C. Croce,et al.  Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. , 1996, Cancer research.

[24]  M. Andreeff,et al.  Activation of p21WAF1/Cip1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis. , 1995, Oncogene.

[25]  M. Hasegawa,et al.  Dephosphorylation of fetal-tau and paired helical filaments-tau by protein phosphatases 1 and 2A and calcineurin. , 1995, Journal of biochemistry.

[26]  C. Croce,et al.  Inactivation of Bcl-2 by phosphorylation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Nilsson,et al.  Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U‐937 lymphoma cell line without overexpression of the 170‐KDa P‐glycoprotein , 1994, International journal of cancer.

[28]  John Calvin Reed.  Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[29]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[30]  M. Ishiyama,et al.  A New Sulfonated Tetrazolium Salt That Produces a Highly Water-Soluble Formazan Dye , 1993 .

[31]  T. Tsuruo,et al.  Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM. , 1992, The Journal of urology.

[32]  Richie Jp.  Intravesical chemotherapy. Treatment selection, techniques, and results. , 1992 .

[33]  P. Twentyman.  Cyclosporins as drug resistance modifiers. , 1992, Biochemical pharmacology.

[34]  C. Klee,et al.  Serine/threonine phosphatases in the nervous system , 1991, Current Opinion in Neurobiology.

[35]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[36]  W. Anderson,et al.  Ca2+-induced hydrophobic site on calmodulin: application for purification of calmodulin by phenyl-Sepharose affinity chromatography. , 1982, Biochemical and biophysical research communications.

[37]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[38]  K. Naito,et al.  [In vitro culture of malignant tumor tissues from the human urinary tract (author's transl)]. , 1977, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[39]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[40]  J. Bubeník,et al.  Established cell line of urinary bladder carcinoma (T24) containing tumour‐specific antigen , 1973, International journal of cancer.

[41]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[42]  B. Altay,et al.  The best management of superficial bladder tumours: Comparing TUR alone versus TUR combined with intravesical chemotherapy modalities? , 2004, International Urology and Nephrology.

[43]  M. Guillaume Wientjes,et al.  Bladder tissue pharmacokinetics of intravesical taxol , 1997, Cancer Chemotherapy and Pharmacology.

[44]  Jessie L.-S. Au,et al.  Pharmacologic effects of paclitaxel in human bladder tumors , 1997, Cancer Chemotherapy and Pharmacology.

[45]  E. White,et al.  Life, death, and the pursuit of apoptosis. , 1996, Genes & development.

[46]  P. Cohen.  The structure and regulation of protein phosphatases. , 1989, Annual review of biochemistry.